The European Commission (EC) has approved a combination therapy for the treatment of metastatic colorectal cancer.  Braftovi (encorafenib) has been approved in combination with cetuximab and FOLOX for the first-time treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).  The approval is based on the results from the Phase III BREAKWATER trial, which assessed the efficacy and safety […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!